DK2901341T3 - Identifikation af tumorbeskyttelsesepitoper til behandling af cancere - Google Patents

Identifikation af tumorbeskyttelsesepitoper til behandling af cancere Download PDF

Info

Publication number
DK2901341T3
DK2901341T3 DK13840946.1T DK13840946T DK2901341T3 DK 2901341 T3 DK2901341 T3 DK 2901341T3 DK 13840946 T DK13840946 T DK 13840946T DK 2901341 T3 DK2901341 T3 DK 2901341T3
Authority
DK
Denmark
Prior art keywords
epitopes
identification
cancer treatment
tumor protection
tumor
Prior art date
Application number
DK13840946.1T
Other languages
English (en)
Inventor
Pramod K Srivastava
Ion Mandoiu
Fei Duan
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Application granted granted Critical
Publication of DK2901341T3 publication Critical patent/DK2901341T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK13840946.1T 2012-09-28 2013-09-27 Identifikation af tumorbeskyttelsesepitoper til behandling af cancere DK2901341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261707295P 2012-09-28 2012-09-28
PCT/US2013/062100 WO2014052707A2 (en) 2012-09-28 2013-09-27 Identification of tumor-protective epitopes for the treatment of cancers

Publications (1)

Publication Number Publication Date
DK2901341T3 true DK2901341T3 (da) 2019-07-15

Family

ID=50389139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13840946.1T DK2901341T3 (da) 2012-09-28 2013-09-27 Identifikation af tumorbeskyttelsesepitoper til behandling af cancere

Country Status (9)

Country Link
US (2) US10501801B2 (da)
EP (1) EP2901341B1 (da)
JP (2) JP6501708B2 (da)
AU (2) AU2013323368B2 (da)
DK (1) DK2901341T3 (da)
ES (1) ES2737757T3 (da)
HR (1) HRP20191182T1 (da)
LT (1) LT2901341T (da)
WO (1) WO2014052707A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
CN105358708B (zh) * 2013-03-14 2024-07-16 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US9990715B2 (en) 2014-04-04 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapy targeted to promote a systemic abscopal effect
WO2016040110A1 (en) 2014-09-10 2016-03-17 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
EP3302574A4 (en) * 2015-05-26 2018-10-17 Advaxis, Inc. Personalized delivery vector-based immunotherapy and uses thereof
EP3323070B1 (en) * 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
US20180237861A1 (en) * 2015-08-13 2018-08-23 Champions Oncology, Inc. Personalized treatment of diseases and disorders
CA3003251A1 (en) 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
AU2016339022B2 (en) 2015-10-12 2020-09-10 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
EP3431595A4 (en) * 2016-03-15 2019-11-20 Repertoire Genesis Incorporation MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
JP7197481B2 (ja) 2016-11-30 2022-12-27 アドバクシス, インコーポレイテッド 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法
US12072337B2 (en) 2017-05-30 2024-08-27 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522594A3 (en) * 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
US8140270B2 (en) * 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
HRP20211595T1 (hr) * 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers

Also Published As

Publication number Publication date
JP2019058190A (ja) 2019-04-18
EP2901341A4 (en) 2016-10-05
EP2901341B1 (en) 2019-04-10
US20150252427A1 (en) 2015-09-10
AU2019204354A1 (en) 2019-07-11
LT2901341T (lt) 2019-09-25
US20200017922A1 (en) 2020-01-16
AU2013323368A1 (en) 2015-04-09
ES2737757T3 (es) 2020-01-15
EP2901341A2 (en) 2015-08-05
HRP20191182T1 (hr) 2019-10-04
JP6501708B2 (ja) 2019-04-17
US10501801B2 (en) 2019-12-10
WO2014052707A2 (en) 2014-04-03
WO2014052707A3 (en) 2015-05-14
JP2015533082A (ja) 2015-11-19
AU2013323368B2 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
DK2901341T3 (da) Identifikation af tumorbeskyttelsesepitoper til behandling af cancere
IL289300A (en) Combination therapy for treating cancer
IL288181A (en) Cancer treatment methods
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK3046583T3 (da) Viruslignende partikelkonjugater til behandling af tumorer
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK2717941T3 (da) Behandling af cancer
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
DK2785349T3 (da) Kombinationsbehandling af cancer
HUE045314T2 (hu) Kombinációs terápia rák kezelésére
KR102104197B9 (ko) 난소암의 치료를 위한 항혈관신생 요법
DK3305285T3 (da) Anti-androgener til behandlingen af ikke-metastatisk kastrationsresistent prostatakræft
EP3967315C0 (en) AKKERMANSIA MUCINIPHILA FOR THE TREATMENT OF CANCER
DK3077544T3 (da) Rationelt-baseret design af en målrettet terapi til cancer
DK3511004T3 (da) Kombineret præparat til behandling af cancer
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
DK3290035T3 (da) Procaspase-kombinationsterapi til behandling af cancer
DK2892535T3 (da) Fremgangsmåde til adjuverende cancerbehandling
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft